December 22, 2017
Lead candidate, light-activated AU-011, currently being investigated in Phase 1b/2 study to treat ocular melanoma, an orphan indication Funding to support ongoing clinical development, enabling buildout of company infrastructure and GMP manufacturing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle...


Professor wants to develop a radioactive precision missile to target brain cancer
21. February 2020
New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge